Avalo Therapeutics (AVTX) Corporate presentation summary

Strategic focus and pipeline

• Advancing novel IL-1β therapies for immune-mediated inflammatory diseases, with a focus on hidradenitis suppurativa (HS).

• Two lead candidates: abdakibart (AVTX-009) with positive Phase 2 data in HS, and AVTX-010, a long-acting anti-IL-1β mAb targeting IND submission in 1H 2027.

• Targeting high-growth, high-unmet-need indications, with the HS market projected to exceed $10B by 2035.

• Exploring IL-1β inhibition for additional indications with strong clinical rationale.

• Well-capitalized with $431.3M financing in May 2026, supporting operations into 2029.

Abdakibart clinical data and competitive positioning

• Abdakibart demonstrated statistically significant efficacy in Phase 2 LOTUS study for moderate-to-severe HS, with HiSCR75 response rates of 42.2–42.9% vs. 25.6% for placebo at week 16.

• HiSCR50 response rates were 59.0–64.3% for abdakibart vs. 40.7% for placebo, both statistically significant.

• Efficacy observed as early as week 4 and consistent across patients with or without prior biologic exposure.

• Cross-trial comparisons suggest abdakibart may offer leading efficacy among approved and pipeline HS therapies.

• Monthly dosing regimen is differentiated and patient-friendly compared to competitors.

Safety and tolerability

• Abdakibart was well-tolerated in ~500 patients across Phase 1 and 2, with adverse event rates similar to placebo.

• No increased risk of neutropenia, serious or opportunistic infections, or major adverse cardiovascular events.

• Most common adverse events were headache and nausea.